Darovasertib
| CAS No. | 1874276-76-2 | Cat. No. | BCP20781 |
| Name | Darovasertib | ||
| Synonyms | LXS196; LXS-196; LXS 196; IDE196; IDE 196;IDE-196;NVP-LXS196; NVPLXS196; NVP LXS196; | ||
| Formula | C22H23F3N8O | M. Wt | 472.48 |
| Description | LXS-196 is a potent and orally active protein kinase C inhibitor for the treatment of uveal melanoma. Upon oral administration, protein kinase C inhibitor LXS196 binds to and inhibits PKC, which prevents the activation of PKC-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC, a serine/threonine protein kinase overexpressed in certain types of cancer cells, is involved in tumor cell differentiation, proliferation, invasion and survival. | ||
| Pathways | TGF beta/Smad Epigenetics | ||
| Targets | PKC | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.